Johnson & Johnson (JNJ)
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic, is now breaking out of a multi-year consolidation phase.
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
Johnson & Johnson is attempting to resolve talc lawsuits through bankruptcy for a third time. This time around, it's letting claimants vote on its proposed settlement.
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
4 Positives For Johnson & Johnson
Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too.
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Johnson & Johnson, the pharmaceutical giant with a 3.21% dividend yield, released financial results for Q2 2024 that exceeded my expectations. Its oncology franchise revenue was $5.09 billion for the three months ended June 30, 2024, an increase of 15.7% year-on-year. For example, sales of Darzalex, an anticancer medication, were $2.88 billion in the second quarter of 2024, up 18.4% year-on-year.
Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat?
Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.82 per share, compared to our estimates of $22.5 billion and $2.72, respectively.
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.
3 Dividend Stocks That Demand Investor Attention
Dividend stocks pay dividends to their shareholders, representing a portion of the company's profits. Not all companies offer dividends.
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.
Is Johnson & Johnson a Buy Now?
Johnson & Johnson reported results from the second quarter of 2024 on Wednesday, July 17. U.S. pharmaceutical sales grew by nearly 9% year over year in the second quarter.
2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold Forever
Starbucks is experiencing weak sales this year, but it has plenty of opportunities to keep growing over the long term. Johnson & Johnson's focus on allocating capital to high-return opportunities has driven a 60-plus year track record of dividend growth.
